What Can Investors Expect From Cyclacel Pharma (NASDAQ:CYCC) Shares After Ladenburg Thalmann’s New Coverage?

September 8, 2018 - By Billy Entrekin

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Logo

How Ladenburg Thalmann Currently Rates Cyclacel Pharma (NASDAQ:CYCC)

In a research report issued today, Ladenburg Thalmann analysts has started Cyclacel Pharma (NASDAQ:CYCC) coverage with “Buy” rating.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Ratings Coverage

Among 2 analysts covering Cyclacel Pharmaceuticals (NASDAQ:CYCC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cyclacel Pharmaceuticals has $8 highest and $700 lowest target. $7.50’s average target is 390.20% above currents $1.53 stock price. Cyclacel Pharmaceuticals had 3 analyst reports since March 29, 2018 according to SRatingsIntel. The stock of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has “Buy” rating given on Thursday, March 29 by H.C. Wainwright. The company was maintained on Tuesday, May 15 by H.C. Wainwright.

The stock increased 6.99% or $0.1 during the last trading session, reaching $1.53. About 102,943 shares traded or 92.84% up from the average. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has declined 70.43% since September 8, 2017 and is downtrending. It has underperformed by 83.00% the S&P500.

Analysts await Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) to report earnings on November, 8. They expect $-0.11 EPS, up 87.91 % or $0.80 from last year’s $-0.91 per share. After $-0.16 actual EPS reported by Cyclacel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -31.25 % EPS growth.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company has market cap of $18.36 million. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. It currently has negative earnings. The Company’s oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors.

More notable recent Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For September 5, 2018” on September 05, 2018, also Nasdaq.com with their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris …” published on September 05, 2018, Nasdaq.com published: “Cyclacel Pharmaceuticals to Present at the 20th Annual HC Wainwright Global Investment Conference” on August 29, 2018. More interesting news about Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) were released by: Nasdaq.com and their article: “Investor Expectations to Drive Momentum within Global Medical REIT, Cyclacel Pharmaceuticals, Super Micro …” published on August 16, 2018 as well as Benzinga.com‘s news article titled: “40 Stocks Moving In Wednesday’s Mid-Day Session” with publication date: September 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.